Aldeyra Therapeutics, Inc.(NASDAQ : ALDX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-2.32%||10.52||0.7%||$735.39m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.60%||201.58||1.9%||$414.73m|
|GILD||Gilead Sciences, Inc.||-2.21%||68.29||1.0%||$401.30m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.46%||574.61||2.7%||$353.89m|
|NTLA||Intellia Therapeutics, Inc.||3.53%||141.85||2.3%||$263.90m|
|CRSP||CRISPR Therapeutics AG||1.70%||121.02||0.6%||$144.72m|
|EXAS||EXACT Sciences Corp.||-3.64%||107.84||18.1%||$123.59m|
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.